Arbutus: IP Drama With High Stakes
Source: SeekingAlpha
2025-09-15 16:27:30 ET
Investment Thesis
Arbutus Biopharma, headquartered in Warminster, Pennsylvania, is a clinical-stage biopharmaceutical company . Its main focus is on expertise in liposomal drug delivery and RNA interference. Arbutus owns a broad and diverse patent portfolio covering various functional aspects of lipid nanoparticle (LNP) technology. LNP technology is mainly known as being used in mRNA-based COVID-19 vaccines made by Moderna and Pfizer/BioNTech . In addition, Arbutus is also developing drugs for chronic hepatitis B virus infection (HBV)....
Read the full article on Seeking Alpha
For further details see:
Arbutus: IP Drama With High Stakes
Arbutus Biopharma Corporation
NASDAQ: ABUS
ABUS Trading
2.71% G/L:
$4.715 Last:
981,321 Volume:
$4.66 Open:
ABUS Latest News
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
November 13, 2025 07:30:00 am
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 07, 2025 08:00:00 am
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
ABUS Stock Data
$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster
